

Metabolomics of fecal samples: a practical consideration

Article

Accepted Version

Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0

Matysik, S., Le Roy, C. I., Liebisch, G. and Claus, S. P. (2016) Metabolomics of fecal samples: a practical consideration. Trends in Food Science and Technology, 57. pp. 244-255. ISSN 0924-2244 doi: 10.1016/j.tifs.2016.05.011 Available at <https://centaur.reading.ac.uk/65839/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.1016/j.tifs.2016.05.011>

Publisher: Elsevier

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Accepted Manuscript

Metabolomics of fecal samples: a practical consideration

Silke Matysik, Caroline Ivanne Le Roy, Gerhard Liebisch, Dr Sandrine Paule Claus

PII: S0924-2244(16)30198-4

DOI: [10.1016/j.tifs.2016.05.011](https://doi.org/10.1016/j.tifs.2016.05.011)

Reference: TIFS 1813

To appear in: *Trends in Food Science & Technology*

Received Date: 29 August 2015

Revised Date: 6 April 2016

Accepted Date: 16 May 2016

Please cite this article as: Matysik, S., Le Roy, C.I., Liebisch, G., Claus, S.P., Metabolomics of fecal samples: a practical consideration, *Trends in Food Science & Technology* (2016), doi: 10.1016/j.tifs.2016.05.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Metabolomics of fecal samples: a practical consideration**

2

3 Silke Matysik¹, Caroline Ivanne Le Roy², Gerhard Liebisch¹, Sandrine Paule

4 Claus^{2*}

5

6 1 Institute of Clinical Chemistry and Laboratory Medicine, University of

7 Regensburg, Germany.

8 2 Department of Food and Nutritional Sciences, The University of Reading,

9 Whiteknights campus, PO Box 226, Reading RG6 6AP, UK.

10

11 * Corresponding author:

12 Dr Sandrine Claus, s.p.claus@reading.ac.uk, +44 (0) 118 378 8717

13

14 **Key words:** Metabolomics, Lipidomics, Feces, Methods

15

16

ABSTRACT**Background**

Metabolic profiling is becoming increasingly popular to identify subtle metabolic variations induced by diet alterations and to characterize the metabolic impact of variations of the gut microbiota. In this context, fecal samples, that contain unabsorbed metabolites, offer a direct access to the outcome of diet - gut microbiota metabolic interactions. Hence, they are a useful addition to measure the ensemble of endogenous and microbial metabolites, also referred to as the hyperbolome.

Scope and Approach

Many reviews have focused on the metabolomics analysis of urine, plasma and tissue biopsies; yet the analysis of fecal samples presents some challenges that have received little attention. We propose here a short review of current practices and some practical considerations when analyzing fecal material using metabolic profiling of small polar molecules and lipidomics.

Key Findings and Conclusions

To allow for a complete coverage of the fecal metabolome, it is recommended to use a combination of analytical techniques that will measure both hydrophilic and hydrophobic metabolites. A clear set of guidelines to collect, prepare and analyse fecal material is urgently needed.

39 Highlights

- 40 1. Untargeted metabolic profiling of fecal material is robustly achieved using
41 NMR-based metabolomics
- 42 2. Mass spectrometry is mostly used for targeted metabolic profiling of a
43 class of molecules for deep coverage and high sensitivity
- 44 3. Lipidomics profiles are extremely complex as they contain a mixture of
45 endogenous, diet-related and microbial lipids that may be of interest for
46 bacterial identification

47

INTRODUCTION

The gut microbiota is a highly metabolically active community of micro-organisms inhabiting all niches along the intestine, that is now recognized as a critical regulator of its host homeostasis.(O'Hara & Shanahan, 2006) It has been estimated that the gut microbiota as a whole contains 100 times more genes than human cells, hence its potential to be a key metabolic player. It is therefore expected that modifying the gut microbial balance would induce a shift in the gut metabolic environment that can in turn affect our own metabolism.

The gut microbiota composition varies considerably over a lifetime.(Yatsunen et al., 2012) It takes approximately two years to a newborn to acquire a stable GM population(Palmer, Bik, DiGiulio, & Relman, 2007) that will evolve through life under the pressure of various factors such as, for instance, diet, lifestyle and exposure to antibiotics, all commonly referred to as the 'exposome'. (Claesson et al., 2011; Claus & Swann, 2013; Lozupone, Stombaugh, Gordon, & Jansson, 2012) Later in life, a loss of microbial diversity is generally observed with senescence. (Biagi, Candela, Fairweather-Tait, Franceschi, & Brigidi, 2011; Claesson et al., 2011) As recently demonstrated, even perturbations of the circadian cycle have been observed to affect the balance of the gut microbial community. (Mukherji, Kobiita, Ye, & Chambon, 2013; Voigt et al., 2014)

Diet is the main factor influencing gut microbiota composition since it provides microorganisms with their main organic carbon source.(Flint, Duncan, Scott, & Louis, 2015) This connection was recently further evidenced by a study demonstrating that a drastic change of diet such as switching from vegetarian to carnivorous and inversely can profoundly reorient the GM ecosystem in a very short period of time.(David et al., 2015) Thus, along genetic and other

environmental factors, diet strongly contributes to the unique character of every individual's gut microbiota.

Bacteria have a high metabolic activity that generates a wide range of products such as organic acids, alcohols and gas that may become available for the host or other commensal bacteria for cross-feeding. This symbiotic activity shapes the gut metabolic environment. Complex carbohydrates, that cannot be digested in the upper gastrointestinal track and are a major source of carbon for colonic bacteria.(Scott, Duncan, & Flint, 2008) Their fermentation results in the production of short chain fatty acids (SCFAs: acetate, propionate, butyrate and valerate) that play an important role in human health.(Besten, van Eunen, Groen, & Venema, 2013) Other food components such as lipids and proteins can largely impact the composition of the gut microbiota and its metabolic activity.(Sonnenburg & Sonnenburg, 2014) Endogenous secretions such as the bile acids contained in bile are important regulators of the gut microbiota. Reciprocally, gut bacteria are known to extensively alter the structure of sterols that leads to the formation of secondary and tertiary bile acids.(Sayin et al., 2013) This is an example of a major gut microbiota-host interplay that contributes to regulating the absorption of dietary lipids during digestion. Hence, the diet-gut microbiota interaction plays a key role in the metabolic homeostasis of its host. It is therefore of utmost importance to understand the biological mechanisms that underlie this complex relationship. Systems biology approaches that study a system as a whole (e.g. a micro-organism within a host, the interactions occurring within a community of bacteria etc.) are increasingly popular to decipher these interactions. In particular, metabolic profiling techniques are tremendously useful to understand the metabolic pathways

regulated through the host-gut microbiota interaction. A variety of sample types ranging from biofluids to tissue biopsies can be analyzed to capture the systemic metabolic response to the exposome. Of particular interest, feces are easily accessible and provide a non-invasive window to study the outcome of the diet-gut microbiota-host interaction through the analysis of remaining unabsorbed metabolites. Yet, the analysis of fecal samples for metabolic profiling has received little attention. In this review, we will explore the dominant technologies that are commonly applied to assess the fecal metabolome and discuss about practical aspects that must be considered when dealing with this material.

NMR-based metabolomics of fecal samples

Metabolic profiling, also referred to as metabolomics, is mostly achieved using two analytical platforms: nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) to evaluate the metabolic composition of a chosen biological matrix. These techniques allow the simultaneous measurement of a wide range of metabolites in a sample, and when combined, offer a large coverage of the metabolome (i.e. the set of metabolites in a sample).

Untargeted metabolic profiling by ^1H NMR spectroscopy measures all metabolites with nonexchangeable protons that are present in a sample in a relatively high concentration (in the micromolar range). Because it is highly reproducible, is cost effective and usually requires only a few simple preparation steps, NMR-based metabolic profiling has been widely applied to the analysis of virtually all biological matrices, including feces. (Li et al., 2011; Martin et al., 2010; Saric et al., 2008)

In humans, ^1H NMR-based metabolic profiling of fecal material has been successfully applied to assess the impact of the composition of the gut microbiota on the gut metabolic environment in the context of ulcerative colitis (UC) and irritable bowel syndrome (IBS). (Le Gall et al., 2011) A similar approach was applied to monitor the gut microbial metabolic activity in elderly (Claesson et al., 2012). In this study, it was possible to cluster patients according to their community setting (length of hospital care) based on fecal water profiling. A recent study also demonstrated the possibility of evaluating independent bacterial contributions at a species level to the gut metabolic environment using this technique. (Le Roy et al., 2015). Applied to the monitoring of probiotic consumption, it was possible to detect faecal metabolic modifications in response to increased *Bifidobacterium* in the colon (Ndagijimana et al., 2009)

In animal models, profound reorientation of the gut microbial community induced by antibiotics in mice was associated to modifications of fecal metabolic profiles measured by the same technique. This was mainly associated to a modification in the fecal content in amino acids and SCFAs. (Yap et al., 2008). Similarly, Romick-Rosendale et al., (Romick-Rosendale et al., 2009) also showed a modification of murine fecal metabolic profiles in response to antibiotic treatments. NMR-based metabonomics analysis of fecal water also proved to be able to differentiate age groups in mice. (Calvani et al., 2014) Finally NMR-based metabonomics can be applied to nutrition (also referred to as nutrimentabonomics) (Claus & Swann, 2013) to access modification of the gut metabolic environment in response to diet modulation. As an example, a study by De Filippis et al., (De Filippis et al., 2015) used NMR-based metabonomics to evaluate the impact of a Mediterranean diet on gut microbiota metabolic activity.

The study demonstrated that following a Mediterranean diet improved the detection of SCFAs in fecal waters compared with a western diet. Similarly, fecal metabolic modifications have been observed in response to food supplementation investigated in *in vitro* gut models. (Frost et al., 2014).

Since fecal samples contain a complex mixture of metabolites, most NMR-based metabolic profiling studies use a selective NOESY experiment with water presaturation applied during recycle delay and mixing time to detect signals caused by small molecular weight molecules as well as some lipids. This is often referred to as the NOESYPR1D experiment [RD-90°-t₁-90°-t_M-90°-ACQ], where RD is the recycle delay, t₁ a short interval of about 3 μs, t_M the mixing time of approximately 100 ms and ACQ the FID acquisition period. Interestingly, a number of studies investigating fecal samples have also used a CPMG (Carr-Purcell-Meiboom-Gill) experiment, (Bjerrum et al., 2014; Li et al., 2011) which uses t₂ filtering to reduce signal resonance from large macromolecules. (Meiboom & Gill, 1958) However, this should be considered with care since the number of loops and length of echo time that must be optimized for each CPMG experiment would determine the signal/noise ratio, therefore preventing absolute quantification. This is not an issue when only relative quantifications are needed.

Preparation of fecal material for metabolomics studies

Recently, Deda et al. reviewed sample preparation methods for fecal samples for metabolomic analysis. (Deda, Gika, Wilson, & Theodoridis, 2015) They provided a comprehensive overview of fecal sample preparation for NMR, GC-MS and LC-MS analysis including some critical aspects and specific requirement of the different technologies. Therefore, we will not cover sample preparation in details here but

a summary of the protocols and methods used in previously published research papers are presented in Table 1. However, it is noteworthy that this review highlighted the lack of consensus about sample preparation for both metabolic profiling technologies. For sample extraction, it seems that a dilution of 1 volume of feces material for 2 volumes of PBS buffer is most commonly used. The buffer is generally composed of a mixture of H₂O and D₂O (minimum 10 %) in various amounts, with an adjusted pH of 7.4 and an internal standard to serve as NMR reference. The most common internal reference is 3-(trimethylsilyl)-2,2,3,3-propionate-d₄ (TSP). Deda et al. discuss that TSP signal intensity can be affected by pH but so far, the only alternative is 2,2-dimethyl-2-silapentane-5-sulfonate-d₆ (DSS). However, unlike TSP, DSS has multiple small resonances in addition to the main resonance at 0 ppm that may interfere with other signals and therefore it should be used at a very low concentration (0.01% would be recommended). Homogenization of fecal material can be done directly in the NMR buffer that will be used for NMR analysis, minimizing the number of sample processing steps that may alter metabolic profiling. However, it also appears that a water/methanol extraction tends to improve the overall recovery of fecal metabolites. Nevertheless it was also argued in a publication by Jacobs et al., (Jacobs et al., 2007) that methanol extracts were less representative of the real metabolic composition of the fecal water encounter in the colon and therefore of the metabolite pool that interacts with the intestinal membrane.

Mass spectrometry-based metabolomics of fecal samples

Untargeted metabolic profiling using MS-based techniques is more sensitive than NMR (in the nanomolar range) but often generates a large amount of unknown signals and as a consequence, these techniques have been mostly used for

targeted metabolomics, where the method is optimized to the detection of a specific class of samples. MS-based metabolic profiling is usually achieved using either gas chromatography (GC-MS) or liquid chromatography (LC-MS).

GC-MS based metabolomics

The group of Sébédio presented two GC-MS methods to analyze the metabolome of fecal water. In their first study they used an ethyl chloroformate derivatization (Gao et al., 2009). In fecal water samples of healthy subjects 73 compounds were identified and thereof 34 validated by reference standards. The second study applied trimethylsilylation and identified 133 compounds (including amino acids, carbohydrates short and long chain fatty acids and phenolics) in human fecal water and the majority validated by authentic standards (Gao, Pujos-Guillot, & Sébédio, 2010). In both studies several extraction conditions were tested and the highest recovery of metabolites detected for neutral and basic pH which was confirmed also by others (Deda et al., 2015). However, it has been suggested that increasing pH from 6 to 7 may decrease the loss of volatile SCFA during lyophilization (Gao, Pujos-Guillot, & Sébédio, 2010).

Phua et al. presented a GC-TOF-MS analysis of feces after freeze drying followed by oximation and silylation (Phua, Koh, Cheah, Ho, & Chan, 2013). The authors argue that removal of a variable content of water increased the reproducibility of sample preparation. They identified 107 metabolites by matching with different mass spectra libraries. However, only a few analytes were confirmed by reference substances. This method was applied in detection of colorectal cancer (Phua et al., 2014). Main markers for CRC differentiation include decreased level of fructose, nicotinic acid and linoleic acid in CRC patients.

Using a similar methodology, Weir et al. analyzed the fecal metabolome in CRC patients (Weir et al., 2013). Metabolite identification was based on database matching. In agreement with Phua et al. they detected decreased linoleic acid in CRC patients compared to healthy controls. Moreover, reduced level of oleic and elaidic acids were found in CRC patients. In contrast to these fatty acids (FAs) myristic acid and several amino acids were increased in CRC patients. It is noteworthy that fatty acid identification does not differentiate double bond positions.

A very efficient approach to analyze volatile organic compounds (VOC) of feces is headspace solid-phase microextraction (SPME). Volatile metabolites are adsorbed to polymer coated fibers which are analyzed by GC-MS. Typically the analyte spectrum includes hydrocarbons, alcohols, aldehydes and organic acids (primarily short chain) and their esters. Dixon et al. tested different fibers to get a comprehensive coverage of VOCs (Dixon et al., 2011). Ahmed et al investigated fecal VOCs in patients with irritable bowel syndrome, active Crohn's disease, ulcerative colitis and healthy controls (Ahmed, Greenwood, de Lacy Costello, Ratcliffe, & Probert, 2013). They identified 240 metabolites which allowed a differentiation of patients with irritable bowel syndrome from patients with inflammatory bowel diseases and healthy controls.

LC-MS based metabolomics

In contrast to GC-based methods, LC-MS usually does not require metabolite derivatization but is restricted to analytes containing polar groups. Cao et al. used UPLC-MS/TOF-MS to analyze the fecal metabolome in patients with liver cirrhosis and hepatocellular carcinoma (HCC) (Cao et al., 2011). Fecal samples were homogenized, centrifuged and injected after filtration. Metabolic features

were analyzed by multivariate data analysis. Chenodeoxycholic acid, 7-ketolithocholic acid, urobilinogen, urobilin, lysophosphatidylcholine (LPC) 16:0 and 18:0 were found to discriminate between healthy controls and patients with liver cirrhosis and HCC. Whereas LPC species were found in increased levels, the other discriminatory markers were decreased in the patient samples. The identities of these markers were confirmed by comparison of chromatographic retention and product ion spectra with authentic standards.

A study by Jimenez-Girón investigated changes in the fecal metabolome related to the consumption of red wine (Jiménez-Girón et al., 2015). Feces samples were analyzed after mixing with saline solution, centrifugation and filtration by UHPLC-TOF-MS. Mass features were subjected to statistical analysis and 37 metabolites were found to be related to wine intake. Metabolite identification was performed by database searching and confirmation by authentic standards. This way 14 metabolites could be identified tentatively, 6 mass features match to standards (m/z and retention time).

The fecal metabolome of rats with chronic renal failure were analyzed by Zhao et al. (Zhao, Cheng, Wei, Bai, & Lin, 2012). Homogenized fecal samples were extracted with acetonitrile and analyzed by UPLC-Q-TOF-MS. Both polarities including fragment ions were recorded and used for identification and validation of mass features. Except an increase of adenine (used to induce kidney failure), 8 lipid metabolites were found decreased in rats with chronic renal failure.

An interesting approach to profile amine- and phenol-containing metabolites was presented recently by Su and colleagues (Su et al., 2015). Dried fecal samples are extracted sequentially with water and acetonitrile followed by derivatization with dansyl chloride. As an internal standard an aliquot of a

pooled fecal extract was added which was derivatized with ^{13}C -labelled dansyl chloride. Dansylation improves both LC separation efficiency and MS response of the compounds. 6200 peaks were detected in 237 different samples and 67 metabolites (mainly amino acids) were identified based on mass and retention time matching to a dansyl standard library.

In summary, both GC- and LC-based metabolomics studies are able to discover a number of differentially regulated metabolic features in fecal samples in various studies. However frequently, only a few of these features could be identified. Moreover, several studies did not prove the identity by authentic standards but only by matching of m/z values to database entries. In general, GC-MS based studies identify an increased number of metabolites which may partly reflect the superior chromatographic resolution and peak shape of GC compared to LC methods. This allows a more reliable extraction and comparison of metabolic features between different samples. Additionally, GC usually provides mass spectra generated by ionization-induced fragmentation that are useful for metabolite identification. A disadvantage of GC analyses is a more laborious sample preparation including the need of derivatization as a potential source of artifacts. Conversely, GC-MS clearly shows advantages compared to LC-MS in terms of deleterious matrix effects. So it is generally accepted that quantification of analytes by LC-MS requires internal standards, ideally stable isotope labeled for each analyte. Therefore a major source of errors of LC-MS metabolic profiling may be related to undiscovered matrix effects especially in heterogeneous sample material like feces. Consequently, in order to provide solid data metabolomics studies should validate their biomarkers by quantitative analysis

using authentic standards and internal standards especially when LC-MS is applied at least in a representative cohort.

Mass spectrometry-based targeted metabolic analysis

In contrast to untargeted analysis, targeted analysis is confined to a limited set of analytes. These methods are optimized for high analyte recoveries during sample preparation and a reproducible, accurate quantification of the target molecules. Most methods rely on internal standards (mandatory for LC-MS), calibration lines and method validation shows their performance.

SCFA

An excellent example for targeted analysis of potential biomarkers is the quantitation of short chain fatty acids (SCFA). A recent study by Han et al. presented a LC-MS/MS method for SCFA quantification in human feces (Han, Lin, Sequeira, & Borchers, 2014). SCFAs are converted to 3-nitrophenylhydrazones (3NHPH) which are separated by reversed phase chromatography and detected in negative ion mode. The method covers 10 straight- and branched chain SCFAs. In an elegant way, this study introduced an internal standard for every analyte by conversion of a standard mixture with a $^{13}\text{C}_6$ -labeled derivatization reagent. This method showed a high reproducibility and analysis of human fecal samples revealed an increased fraction of branched-chain SCFA in T2D patient compared the other analyzed samples.

In contrast to LC-MS/MS analysis, GC-MS may rely on a fewer number of internal standards since matrix effects are less pronounced. A study by Zheng et al. quantified SCFAs and branched-chain amino acids (BCAAs) in feces and other biological materials using D_3 -caproic acid as internal standard (Zheng et al., 2013) after propyl chloroformate derivatization.

Analysis of sterols and bile acids in faeces

Sterols and bile acids belong to another class of analytes studied for a long time in feces by targeted analysis. Cholesterol is an essential component of all mammalian cell membranes and it is the precursor of steroid hormones and bile acids. There has been a long interest in the intestinal metabolism of cholesterol because the gut microbiome is highly involved in the balance between absorption, excretion and metabolism. Between 34-57% of dietary cholesterol is absorbed from the human intestine (Grundy et al., 1977). Fecal excretion of total neutral sterols has been reported to range between 350-900 mg/day, of which 20% is cholesterol. There are several primary sources of fecal cholesterol: unabsorbed from the diet, bile and intestinal epithelium. It is well-known that the luminal cholesterol can be metabolized by the gut microbiota. This cholesterol escaping intestinal absorption is degraded to coprostanol through reduction of the double bond at C-5. (Figure 1) Coprostanone is also produced in a lesser extent. (Eyssen et al., 1974; Lichtenstein, 1990; Gerard, 2013). In human feces, cholesterol derivatives have been reported in the following proportions: coprostanol 65%, cholesterol 20%, coprostanone 10 %. (Figure 1) Other minor derivatives include cholestanone, cholestanol and epicoprostanol.

Many attempts have been made to isolate bacteria capable of reducing cholesterol to coprostanol from human and animal faeces (Snog-Kjaer et al., 1956; Crowther et al., 1973). Certain anaerobic bacteria from human faeces are known to hydrogenate cholesterol in vitro. Cholesterol reduction by common intestinal bacteria such as *Bifidobacterium*, *Clostridium*, and *Bacteriodes* has also been reported and reviewed extensively (Gerard, 2013). In addition, reference values have been generated for fecal excretion of cholesterol and

coprostanol (Benno et al., 2005) to differentiate between high-, low- and non-converters.

Bile acids are derived from cholesterol and are produced by every class of vertebrate animals and show substantial diversity across species (Hofmann et al., 2010). In bile, bile acids rapidly form mixed micelles with secreted cholesterol and phospholipids. Bile acids enter the intestine as di- and trihydroxylated acyl conjugates, in mammals with the amino acids taurine and glycine (Hofmann, 2009). In the intestinal lumen, conjugated bile acids directly affect the microbiota because they exert antimicrobial properties besides stimulating enterocytes to secrete undefined antimicrobial compounds (Hofmann et al., 2006). Conversely, gut bacteria structurally alter bile acids through deconjugation of taurine, glycine and sulfate moieties and hydroxylation of the sterol backbone.

During digestion, bile acids facilitate lipid absorption by stabilizing lipid micelles. Since bile acids have various degrees of hydrophobicity, and therefore various stabilizing properties, the bile acid composition of the bile is an important factor that regulates fat absorption. The enterohepatic cycle of bile acids is a key regulator of hepatic bile acid *de novo* synthesis and cholesterol excretion. Indeed, bile acids undergo extensive reabsorption by active and passive routes so that 95 % of secreted bile acids are reabsorbed daily. Since deconjugated bile acids are less polar, passive diffusion is reduced and it has been shown that active deconjugation by gut bacteria increases the overall excretion of bile acids in feces, hence the role of bacteria in regulating fecal cholesterol loss (Claus et al., 2011; 2008; Kellogg, Knight, & Wostmann, 1970; Sayin et al., 2013). In human, a limited number of commensal bacteria are capable of removing the 7-hydroxyl

group from di- and trihydroxy bile acids and 7-deoxy species are formed. The most common 7-deoxy bile acids are lithocholic and deoxycholic acid. Many excellent reviews exist in the recent literature covering bile acid function, signaling and therapeutic potential (Ridlon et al., 2006; Hofmann et al., 2008; 2009; Trauner et al., 2010; Hagey et al., 2013).

Sample Preparation and Instrumental Strategies for Targeted Metabolomics Analysis

SCFAs are volatile and therefore freeze drying of stool samples may result in lower recovery. Han et al. used homogenized samples and extracted SCFAs by addition of 50% aqueous acetonitrile (Han, Lin, Sequeira, & Borchers, 2014). These extracts were subjected directly to derivatization with 3-nitrophenylhydrazine HCl. Zheng et al. used 0.005 M aqueous NaOH to homogenize fecal samples at 4°C to protect the volatile SCFAs (Zheng et al., 2013). The homogenates were derivatized with propyl chloroformate and extracted with hexane extraction for GC-MS analysis.

Extensive overviews of state-of-the-art methods to analyze fecal steroids can be found in the literature, e.g. (Story & Furumoto, 1991; Perwaiz et al., 2002; Griffiths & Sjövall, 2010). The first and often referred methods for fecal steroid and bile acid analysis were a combination of thin-layer chromatography and gas-liquid chromatography published 1965 by Grundy, Miettinen and co-workers (Grundy et al., 1965; Miettinen et al., 1965). Sample pretreatment included homogenization, saponification and liquid/liquid extraction followed by thin-layer chromatography and trimethylsilylation. Individual components are then quantitatively measured by gas-liquid chromatography equipped with a flame ionization detector. Bile acids underwent a methylation step before thin-layer

chromatography. This approach was applied in many studies for the analysis of endogeneous and exogeneous (labelled) compounds.(Spritz et al., 1965; Grundy et al., 1969). Evrard and Janssen suggested a method for bile acid analysis which took advantage of a different extraction scheme and an alternate derivatization (Evrard & Janssen, 1968). The method is based on heating in presence of acetic acid and extraction with toluene. Quantification was done as methylketone derivatives. In the 1980s methods with subfraction steps have been proposed to isolate taurine and glycine conjugated and sulphated bile acids (Setchell et al., 1983; Owen et al., 1984) using GC analysis. Nowadays, the most common strategies to analyze sterol profiles including cholesterol, coprostanol and coprostanone in faeces are based on GC-MS. The sample preparation protocol includes repeated sampling for better representativeness, a dilution step, hydrolyzation of esterified sterols, extraction with a mixture of hexane and ethanol and derivatization (Lutjohann et al., 1993; Midtvedt et al., 1990; Andrasi et al., 2011). For example, Korpela et al. suggested a very detailed protocol which included a 72 h sampling of faeces, methanol-chloroform extraction, separation of free and esterified sterols with a Lipidex-5000 column, saponification, separation of hydroxylated and oxo-forms by a second column, and trimethylsilyl derivatization followed by GCMS (Korpela, 1982). LC-MS and MS/MS have also been widely exploited for bile acid analysis of human urine, plasma/serum, bile and also feces (Perwaiz et al., 2002; Hagio et al., 2009; Griffiths & Sjövall, 2010). Quantification is best performed by addition of isotope labeled internal standards. These should be added as early as possible in the analytical process so as to account for analyte loss during sample preparation.

Bile acids can usually be extracted from fluids and tissues with ethanol, methanol or acetonitrile. An ethanol fraction may be followed by extraction with a less polar solvent, such as chloroform, to recover less polar bile acid derivatives (e.g., the fatty acid esters) and bile acids remaining in the lipophilic residue (Griffiths et al., 2010). Batta et al. compared different methods to extract fecal bile acids and sterols (Batta et al., 1999) to suggest a simplified method of extraction. However, this is based on the assumption that fecal bile acids are unconjugated (Setchell et al., 1983), which is not a valid assumption for many clinical conditions, especially when subjects have been exposed to oral antibiotic treatments that have affected the gut microbial ecosystem.

Lipidomics

Parallel to metabolomics, lipidomics emerged during the past decade as a specialized discipline. Today virtually a full quantitative coverage of the lipidome is possible by mass spectrometric methods (Wenk, 2010).

In contrast to global metabolomics, lipidomic analysis mostly relies on lipid extracts prepared by extraction with apolar solvents like chloroform (Bligh & Dyer, 1959) or MTBE (Matyash, et al., 2008). The complexity of these extracts is greatly reduced compared to protein precipitates frequently applied for untargeted metabolomics as polar analytes are removed.

Up to now there are only a few studies of the fecal lipidome. Gregory et al. compared different extraction methods for lipidomics profiling by LC-HR-MS (high resolution MS) (Gregory et al., 2013). Stools of preterm infants were homogenized in water and lipophilic metabolites were extracted using either dichloromethane or a MTBE/hexafluoroisopropanol mixture. Additionally, the effect of pressure cycling on the extraction of lipid species was investigated.

Polar species like lyso-lipids showed a higher response after MTBE extraction whereas increased responses were observed after dichloromethane extraction for more hydrophobic species. The effect of pressure cycling does not show a consistent increase of the lipid species response for both extraction methods. Analysis by reversed phase chromatography couple to HR-MS was performed in both positive and negative ion modes. 304 lipid species were identified by unique monoisotopic m/z and retention time including 29 phosphatidylethanolamine (PE), 22 phosphatidylcholine (PC), 14 phosphatidylglycerol (PG), 88 triacylglycerol, 19 diacylglycerol and interestingly 50 ceramide species.

Recently, Davis and colleagues analyzed stools from mice fed a high fat or control diet with or without induction of colitis-associated tumors (Davies et al., 2014). Feces was homogenized by repeated freeze-thawing, minced to powder and extracted with a modified Bligh and Dyer method. Samples were quantified by shotgun lipidomics. However, mass spectra displayed very low intensities. The selection of dioleoyl species of PE, PS, PI as internal standards has to be considered as a potential source of error for quantification since these species may be present in feces (PE and PI 36:2 were detected by Gregory et al. (Gregory et al., 2013)). A general problem of this study and also a number of metabolomics studies is the annotation of lipid species. Davis et al. showed detailed annotations including even double bond positions of the fatty acyls. Such structural differences usually may not be resolved by standard lipidomic or metabolomics methods. Most methods determine the number of carbons and number of double bonds with the acyl chains. Therefore, it is recommended to annotate only structural details which are resolved by the analysis (Liebisch et

al., 2013). Moreover, common shorthand nomenclature provides a standard for reporting and searching of lipid species including deposition in and retrieval from databases.

Figure 2 presents the result of a lipidomic analysis of a fecal sample using a method that has been applied to a variety of sample types such as plasma (Sigrüener et al., 2014), lipoproteins (Scherer, Böttcher, & Liebisch, 2011), cells (Leidl, Liebisch, Richter, & Schmitz, 2008), cell culture (Binder, Liebisch, Langmann, & Schmitz, 2006) and tissues (Hebel et al., 2015). Fecal samples were homogenized including bead-based grinding and subjected to liquid extraction according to Bligh and Dyer (Bligh & Dyer, 1959). Analysis by flow injection ESI-MS/MS using lipid class specific head group scans revealed huge differences between the individual samples. For example, we could find substantial concentrations of PG in some samples whereas other samples showed only minor PG content (Figure 2). Similar observations were made for other lipid classes. Additionally, the method of homogenization and extraction may greatly influence lipid species recovery. So sample preparation may determine whether analysis of lipids is confined to “easily accessible” lipids or includes also “hardly extractable” bacterial lipid. Bacterial lipids could be of particular interest since they are used as chemotaxonomic parameter to classify and identify bacterial (Busse, Denner, & Lubitz, 1996). However, bacterial lipids also increase the complexity of the fecal lipidome. So a number of additional fatty acids usually not or only present at low concentrations in mammalian cells are found in bacteria such as branched chain, cyclopropane and hydroxyl fatty acids. In summary, an accurate analysis of the fecal lipidome poses a great challenge especially due to its high complexity and high variability.

NMR has also been used for structural analyses and quantification of lipid species including lipoproteins (Bou Khalil *et al.*, 2010; Sander *et al.*, 2013; AlaKorpela *et al.*, 1996; Fernando *et al.*, 2010). ^{31}P -NMR is an attractive method to investigate phospholipid molecules due to the fact that all phospholipids have at least one phosphorous nucleus and this NMR active isotope occurs at a natural abundance of 100% and has got a high gyromagnetic ratio. Therefore, high resolution ^{31}P -NMR spectroscopy has successfully been employed to determine the phospholipid composition of tissues and body fluids. Comprehensive reviews with many applications can be found in the literature (Schiller & Arnold, 2002; Schiller *et al.*, 2007). However, we could not identify any study that applied NMR spectroscopy for lipid investigations in fecal samples.

Final considerations

It is noteworthy that although extremely useful and widely used, as illustrated by this review, fecal materials reliably reflect the microbial activity of the distal colon, which is moderately representative of the rest of the gastro-intestinal tract. For example, although it is commonly accepted that SCFAs measured in feces are an indicator of colonic production by gut bacteria, it is important to remember that these metabolites are quickly absorbed by the intestinal membrane and an increased detection in feces may also reflect a poorer absorption. To overcome this issue, metabolic profiling techniques can be applied on luminal content collected in various sections of the gastro-intestinal track, although this implies a more invasive sample collection. Fecal water profiling by NMR spectroscopy has been widely referenced for numerous animal models such as rodents (Romick-Rosendale *et al.*, 2009) and horses (Escalona *et al.*, 2014) as well as humans, (Jacobs *et al.*, 2008) providing a database for future

investigations. This is also extremely useful for similar evaluations performed on fecal waters derived from *in vitro* batch cultures that simulate digestion by the gut microbiota. Even if *in vitro* models are not a perfect representation of the host-gut microbiota interplay, they provide a valuable overview of the microbial activity in the gut in controlled conditions. For instance, metabolic profiling of samples derived from such *in vitro* gut models has been recently applied to compare the impact of diet on human and baboon gut microbial activity.(Frost, Walton, Swann, & Psichas, 2014)

Another important consideration when analyzing feces metabolome, and particularly fecal bile acids, is the irregularity of bile secretion and the inhomogeneity of fecal samples as carefully studied by Setchell et al., who demonstrated that this was strongly correlated with diet patterns (Setchell et al., 1987). This is particularly relevant to human studies since humans tend to have a defined regular feeding pattern with set time and number of meals per day (unlike rodents that tend to feed all night, and from time to time during the day). As a consequence, it is recommended to analyze aliquots of thoroughly homogenized 4–5 day collections of feces.

Finally, since one of the main factors influencing the gut metabolic environment is the microbiome, it is important to assess the microbial composition of the fecal material when possible, using 16S rRNA sequencing or metagenomics when possible, although these methods are not fully quantitative. Such metabolic associations with gut bacteria should also be interpreted carefully as it is not always possible to differentiate the host from the bacterial metabolic activity. This is particularly true for amino acids that can be released by dead host cells or be derived from protein digestion by host and bacterial enzymes. Typical

bacterial metabolites include SCFAs, some organic acids such as formate and by-products of protein degradation such as indole. However, many fecal metabolites derive from host-bacterial co-metabolism, which is typically the case for secondary and tertiary bile acids.

To summarize, the measurement of the fecal metabolome is becoming increasingly popular as it provides an easy estimate of the diet-gut microbiota-host metabolic interaction. However, there is a need for establishing clear guidelines for fecal sample collection, preparation and analysis for metabolic profiling. Both NMR and MS-based metabolic profiling are complementary techniques and none of them to date is able to holistically assess the fecal metabolome. Instead, it is recommended that a combination of methods is used to extend the metabolic coverage.

Acknowledgements

The authors would like to thank Dr Lesli Hingstrup Larsen who provided the sample for lipidomics analysis. This work was supported by the EU FP7 programme of research MyNewGut (613979).

References

- Ahmed, I., Greenwood, R., de Lacy Costello, B., Ratcliffe, N. M., & Probert, C. S. (2013). An investigation of fecal volatile organic metabolites in irritable bowel syndrome. *PLoS One*, 8(3), e58204. doi:10.1371/journal.pone.0058204
- Ala-Korpela, M., Posio, P., Mattila, S., Korhonen, A., & Williams, S. R. (1996). Absolute quantification of phospholipid metabolites in brain-tissue extracts by ¹H NMR spectroscopy. *Journal of Magnetic Resonance, Series B*, 113(2), 184-189.
- Andrási, N., Helenkár, A., Vasanits-Zsigrai, A., Záray, G., & Molnár-Perl, I. (2011). The role of the acquisition methods in the analysis of natural and synthetic steroids and cholic acids by gas chromatography-mass spectrometry. *Journal of Chromatography. A*, 1218(45), 8264-8272. <http://doi.org/10.1016/j.chroma.2011.09.006>
- Batta, A. K., Salen, G., Rapole, K. R., Batta, M., Batta, P., Alberts, D., & Earnest, D. (1999). Highly simplified method for gas-liquid chromatographic quantitation of bile acids and sterols in human stool. *Journal of Lipid Research*, 40(6), 1148-1154.
- Benno, P., Midtvedt, K., Alam, M., Collinder, E., Norin, E., & Midtvedt, T. (2005). Examination of intestinal conversion of cholesterol to coprostanol in 633 healthy subjects reveals an age- and sex-dependent pattern. *Microbial Ecology in Health and Disease*, 17(4).

601

602 Besten, den, G., van Eunen, K., Groen, A. K., & Venema, K. (2013). The role of
603 short-chain fatty acids in the interplay between diet, gut microbiota, and host
604 energy metabolism. *Journal of Lipid Research*, 54(9), 2325-2340.

605

606 Bezabeh, T., Somorjai, R., Dolenko, B., Bryskina, N., Levin, B., Bernstein, C. N., &
607 Smith, I. C. P. (2009). Detecting colorectal cancer by ¹H magnetic resonance
608 spectroscopy of fecal extracts. *NMR in Biomedicine*, 22(6), 593-600.

609

610 Biagi, E., Candela, M., Fairweather-Tait, S., Franceschi, C., & Brigidi, P. (2012).
611 Ageing of the human metaorganism: the microbial counterpart. *Age*, 34(1), 247-
612 267.

613

614 Binder, M., Liebisch, G., Langmann, T., & Schmitz, G. (2006). Metabolic profiling of
615 glycerophospholipid synthesis in fibroblasts loaded with free cholesterol and
616 modified low density lipoproteins. *Journal of Biological Chemistry*, 281(31),
617 21869-21877.

618

619 Bjerrum, J. T., Wang, Y., Hao, F., Coskun, M., Ludwig, C., Günther, U., & Nielsen, O.
620 H. (2014). Metabonomics of human fecal extracts characterize ulcerative colitis,
621 Crohn's disease and healthy individuals. *Metabolomics*, 11(1), 122-133.
622 <http://doi.org/10.1007/s11306-014-0677-3>

623

624 Bligh, E. G., & Dyer, W. J. (1959). A rapid method of total lipid extraction and
625 purification. *Canadian journal of biochemistry and physiology*, 37(8), 911-917.

626

627 Bou Khalil, M., Hou, W., Zhou, H., Elisma, F., Swayne, L. A., Blanchard, A. P., ... &
628 Figeys, D. (2010). Lipidomics era: accomplishments and challenges. *Mass*
629 *spectrometry reviews*, 29(6), 877-929.

630

631 Busse, H. J., Denner, E. B., & Lubitz, W. (1996). Classification and identification of
632 bacteria: current approaches to an old problem. Overview of methods used in
633 bacterial systematics. *Journal of biotechnology*, 47(1), 3-38.

634

635 Calvani, R., Brasili, E., Praticò, G., Capuani, G., Tomassini, A., Marini, F., ... &
636 Miccheli, A. (2014). Fecal and urinary NMR-based metabolomics unveil an aging
637 signature in mice. *Experimental gerontology*, 49, 5-11.

638

639 Cao, G., Zhang, Y., Feng, J., Cai, H., Zhang, C., Ding, M., ... & Cai, B. (2011). A Rapid
640 and sensitive assay for determining the main components in processed *Fructus*
641 *corni* by UPLC-Q-TOF-MS. *Chromatographia*, 73(1-2), 135-141.

642

643 Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery,
644 E., et al. (2011). Composition, variability, and temporal stability of the intestinal
645 microbiota of the elderly. *Proceedings of the National Academy of Sciences*, 108
646 *Suppl 1*, 4586-4591. <http://doi.org/10.1073/pnas.1000097107>

647

648 Claesson, M. J., Jeffery, I. B., Conde, S., Power, S. E., O'Connor, E. M., Cusack, S., ... &
649 Fitzgerald, G. F. (2012). Gut microbiota composition correlates with diet and
650 health in the elderly. *Nature*, 488(7410), 178-184.

- 651 Claus, S. P., & Swann, J. R. (2013). Nutrimetabonomics: Applications for
 652 Nutritional Sciences, with Specific Reference to Gut Microbial Interactions.
 653 *Annual Review of Food Science and Technology*, 4, 381–399.
 654 <http://doi.org/10.1146/annurev-food-030212-182612>
 655
- 656 Claus, S. P., Ellero, S. L., Berger, B., Krause, L., Bruttin, A., Molina, J., et al. (2011).
 657 Colonization-induced host-gut microbial metabolic interaction. *mBio*, 2(2).
 658 <http://doi.org/10.1128/mBio.00271-10>
 659
- 660 Claus, S. P., Tsang, T. M., Wang, Y., Cloarec, O., Skordi, E., Martin, F.-P., et al.
 661 (2008). Systemic multicompartmental effects of the gut microbiome on mouse
 662 metabolic phenotypes. *Molecular Systems Biology*, 4(1), 219.
 663 <http://doi.org/10.1038/msb.2008.56>
 664
- 665 Crowther, J. S., Drasar, B. S., Goddard, P., Hill, M. J., & Johnson, K. (1973). The
 666 effect of a chemically defined diet on the faecal flora and faecal steroid
 667 concentration. *Gut*, 14(10), 790–793.
 668
- 669 David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe,
 670 B. E., et al. (2015). Diet rapidly and reproducibly alters the human gut
 671 microbiome. *Nature*, 505(7484), 559–563. <http://doi.org/10.1038/nature12820>
 672
- 673 Davies, J. M., Hua, H. U., Dheer, R., Martinez, M., Bhattacharya, S. K., & Abreu, M. T.
 674 (2014). Stool Phospholipid Signature is Altered by Diet and Tumors. *PloS one*,
 675 9(12), e114352, doi:10.1371/journal.pone.0114352

676

677 Deda, O., Gika, H. G., Wilson, I. D., & Theodoridis, G. A. (2015). An overview of
678 fecal sample preparation for global metabolic profiling. *Journal of pharmaceutical*
679 *and biomedical analysis*, 113, 137-150.

680

681 De Filippis, F., Pellegrini, N., Vannini, L., Jeffery, I. B., La Storia, A., Laghi, L., ... &
682 Turrone, S. (2015). High-level adherence to a Mediterranean diet beneficially
683 impacts the gut microbiota and associated metabolome. *Gut*, gutjnl-2015.

684

685 Dixon, E., Clubb, C., Pittman, S., Ammann, L., Rasheed, Z., Kazmi, N., et al. (2011).
686 Solid-phase microextraction and the human fecal VOC metabolome. *PLoS One*,
687 6(4), e18471. doi:10.1371/journal.pone.0018471

688

689 Escalona, E. E., Leng, J., Dona, A. C., Merrifield, C. A., Holmes, E., Proudman, C. J., &
690 Swann, J. R. (2015). Dominant components of the Thoroughbred metabolome
691 characterised by ¹H-nuclear magnetic resonance spectroscopy: A metabolite
692 atlas of common biofluids. *Equine veterinary journal*, 47(6), 721-730.

693

694 Evrard, E., & Janssen, G. (1968). Gas-liquid chromatographic determination of
695 human fecal bile acids. *Journal of Lipid Research*, 9(2), 226-236.

696

697 Eyssen, H., & Parmentier, G. (1974). Biohydrogenation of sterols and fatty acids
698 by the intestinal microflora. *The American Journal of Clinical Nutrition*, 27(11),
699 1329-1340.

700

Fernando, H., Kondraganti, S., Bhopale, K. K., Volk, D. E., Neerathilingam, M., Kaphalia, B. S., ... & Shakeel Ansari, G. A. (2010). ¹H and ³¹P NMR lipidome of ethanol-induced fatty liver. *Alcoholism: Clinical and Experimental Research*, 34(11), 1937-1947.

Flint, H. J., Duncan, S. H., Scott, K. P., & Louis, P. (2015). Links between diet, gut microbiota composition and gut metabolism. *Proceedings of the Nutrition Society*, 74(01), 13-22. <http://doi.org/10.1017/S0029665114001463>

Frost, G. S., Walton, G. E., Swann, J. R., Psichas, A., Costabile, A., Johnson, L. P., & Barraclough, T. G. (2014). Impacts of plant-based foods in Ancestral Hominin diets on the metabolism and function of gut microbiota in vitro. *Mbio*, 5(3), e00853-14.

Gao, X., Pujos-Guillot, E., & Sébédio, J (2010). Development of a Quantitative Metabolomic Approach to Study Clinical Human Fecal Water Metabolome Based on Trimethylsilylation Derivatization and GC/MS Analysis. *Analytical Chemistry*, 82(15), 6447. doi:10.1021/ac1006552

Gao, X., Pujos-Guillot, E., Martin, J., Galan, P., Juste, C., Jia, W., & Sébédio, J (2009). Metabolite analysis of human fecal water by gas chromatography/mass spectrometry with ethyl chloroformate derivatization. *Analytical Biochemistry*, 393(2), 163. doi:10.1016/j.ab.2009.06.036

- 725 Gérard, P. (2013). Metabolism of cholesterol and bile acids by the gut microbiota.
 726 *Pathogens*, 3(1), 14–24. <http://doi.org/10.3390/pathogens3010014>
 727
- 728 Gregory, K. E., Bird, S. S., Gross, V. S., Marur, V. R., Lazarev, A. V., Walker, W. A., &
 729 Kristal, B. S (2013). Method Development for Fecal Lipidomics Profiling.
 730 *Analytical Chemistry*, 85(2), 1114. doi:10.1021/ac303011k
 731
- 732 Griffiths, W. J., & Sjövall, J. (2010). Bile acids: analysis in biological fluids and
 733 tissues. *Journal of Lipid Research*, 51(1), 23–41.
 734 <http://doi.org/10.1194/jlr.R001941-JLR200>
 735
- 736 Grundy, S. M., Ahrens, E. H., & Davignon, J. (1969). The interaction of cholesterol
 737 absorption and cholesterol synthesis in man. *Journal of Lipid Research*, 10(3),
 738 304–315.
 739
- 740 Grundy, S. M., & Ahrens, E. H. (1969). Measurements of cholesterol turnover,
 741 synthesis, and absorption in man, carried out by isotope kinetic and sterol
 742 balance methods. *Journal of Lipid Research*, 10(1), 91–107.
 743
- 744 Grundy, S. M., & Mok, H. Y. (1977). Determination of cholesterol absorption in
 745 man by intestinal perfusion. *Journal of Lipid Research*, 18(2), 263–271.
 746
- 747 Grundy, S. M., Ahrens, E. H., & Miettinen, T. A. (1965). Quantitative isolation and
 748 gas--liquid chromatographic analysis of total fecal bile acids. *Journal of Lipid*
 749 *Research*, 6, 397–410.

750

751 Hagey, L. R., & Krasowski, M. D. (2013). Microbial biotransformations of bile
752 acids as detected by electrospray mass spectrometry. *Advances in Nutrition*
753 *(Bethesda, Md.)*, 4(1), 29–35. <http://doi.org/10.3945/an.112.003061>

754

755 Hagio, M., Matsumoto, M., Fukushima, M., Hara, H., & Ishizuka, S. (2009).
756 Improved analysis of bile acids in tissues and intestinal contents of rats using
757 LC/ESI-MS. *Journal of Lipid Research*, 50(1), 173–180.
758 <http://doi.org/10.1194/jlr.D800041-JLR200>

759

760 Han, J., Lin, K., Sequeira, C., & Borchers, C. H. (2015). An isotope-labeled chemical
761 derivatization method for the quantitation of short-chain fatty acids in human
762 feces by liquid chromatography–tandem mass spectrometry. *Analytica chimica*
763 *acta*, 854, 86–94.

764

765 Hebel, T., Eisinger, K., Neumeier, M., Rein-Fischboeck, L., Pohl, R., Meier, E. M., ... &
766 Krautbauer, S. (2015). Lipid abnormalities in alpha/beta2-syntrophin null mice
767 are independent from ABCA1. *Biochimica et Biophysica Acta (BBA)-Molecular and*
768 *Cell Biology of Lipids*, 1851(5), 527–536.

769

770 Hofmann, A. F., & Eckmann, L. (2006). How bile acids confer gut mucosal
771 protection against bacteria. *Proceedings of the National Academy of Sciences of*
772 *the United States of America*, 103(12), 4333–4334.
773 <http://doi.org/10.1073/pnas.0600780103>

774

- Hofmann, A. F., & Hagey, L. R. (2008). Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. *Cellular and Molecular Life Sciences (CMLS)*, 65(16), 2461–2483. <http://doi.org/10.1007/s00018-008-7568-6>
- Hofmann, A. F. (2009). Bile acids: trying to understand their chemistry and biology with the hope of helping patients. *Hepatology*, 49(5), 1403-1418.
- Hofmann, A. F., Hagey, L. R., & Krasowski, M. D. (2010). Bile salts of vertebrates: structural variation and possible evolutionary significance. *Journal of Lipid Research*, 51(2), 226–246. <http://doi.org/10.1194/jlr.R000042>
- Hong, Y. S., Ahn, Y. T., Park, J. C., Lee, J. H., Lee, H., Huh, C. S., ... & Hwang, G. S. (2010). ¹H NMR-based metabonomic assessment of probiotic effects in a colitis mouse model. *Archives of pharmacal research*, 33(7), 1091-1101.
- Jacobs, D. M., Deltimple, N., van Velzen, E., Van Dorsten, F. A., Bingham, M., Vaughan, E. E., & van Duynhoven, J. (2008). ¹H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome. *NMR in Biomedicine*, 21(6), 615–626. <http://doi.org/10.1002/nbm.1233>
- Jiménez-Girón, A., Ibáñez, C., Cifuentes, A., Simó, C., Muñoz-González, I., Martín-Álvarez, P. J., ... & Moreno-Arribas, M. (2015). Estudio del metaboloma fecal tras el consumo moderado y continuado de vino tinto por individuos sanos.

- 799 Kellogg, T. F., Knight, P. L., & Wostmann, B. S. (1970). Effect of bile acid
800 deconjugation on the fecal excretion of steroids. *Journal of lipid research*, 11(4),
801 362-366.
- 802
- 803 Korpela, J. T. (1982). Capillary gas-liquid chromatography of faecal free and
804 esterified neutral sterols. *Scandinavian Journal of Clinical and Laboratory*
805 *Investigation*, 42(6), 529-534.
- 806
- 807 Le Gall, G., Noor, S. O., Ridgway, K., Scovell, L., Jamieson, C., Johnson, I. T., et al.
808 (2011). Metabolomics of Fecal Extracts Detects Altered Metabolic Activity of Gut
809 Microbiota in Ulcerative Colitis and Irritable Bowel Syndrome. *Journal of*
810 *Proteome Research*, 10(9), 4208-4218. <http://doi.org/10.1021/pr2003598>
- 811
- 812 Le Roy, C. I., Štšepetova, J., Sepp, E., Songisepp, E., Claus, S. P., & Mikelsaar, M.
813 (2015). New insights into the impact of Lactobacillus population on host-bacteria
814 metabolic interplay. *Oncotarget*, 6(31), 30545-30556.
- 815
- 816 Leidl, K., Liebisch, G., Richter, D., & Schmitz, G. (2008). Mass spectrometric
817 analysis of lipid species of human circulating blood cells. *Biochimica et*
818 *Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*, 1781(10), 655-664.
- 819
- 820 Li, J. V., Saric, J., Wang, Y., Keiser, J., Utzinger, J., & Holmes, E. (2011).
821 Chemometric analysis of biofluids from mice experimentally infected with
822 *Schistosoma mansoni*. *Parasites & Vectors*, 4, 179. [http://doi.org/10.1186/1756-](http://doi.org/10.1186/1756-3305-4-179)
823 3305-4-179

824

825 Lichtenstein, A. H. (1990). Intestinal cholesterol metabolism. *Annual medicine*
826 22(1)

827

828 Liebisch, G., Vizcaíno, J. A., Köfeler, H., Trötz Müller, M., Griffiths, W. J., Schmitz, G.,
829 & Wakelam, M. J. (2013). Shorthand notation for lipid structures derived from
830 mass spectrometry. *Journal of lipid research*, jlr-M033506.

831

832 Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012).
833 Diversity, stability and resilience of the human gut microbiota. *Nature*,
834 489(7415), 220-230.

835

836 Lütjohann, D., Meese, C. O., Crouse, J. R., & Bergmann, von, K. (1993). Evaluation
837 of deuterated cholesterol and deuterated sitostanol for measurement of
838 cholesterol absorption in humans. *Journal of Lipid Research*, 34(6), 1039–1046.

839

840 Marchesi, J. R., Holmes, E., Khan, F., Kochhar, S., Scanlan, P., Shanahan, F., ... &
841 Wang, Y. (2007). Rapid and noninvasive metabonomic characterization of
842 inflammatory bowel disease. *Journal of proteome research*, 6(2), 546-551.

843

844 Martin, F.-P. J., Sprenger, N., Montoliu, I., Rezzi, S., Kochhar, S., & Nicholson, J. K.
845 (2010). Dietary modulation of gut functional ecology studied by fecal
846 metabonomics. *Journal of Proteome Research*, 9(10), 5284–5295.
847 <http://doi.org/10.1021/pr100554m>

848

- 849 Meiboom, S., & Gill, D. (1958). Modified Spin-Echo Method for Measuring Nuclear
 850 Relaxation Times. *Review of Scientific Instruments*, 29(8), 688.
 851 <http://doi.org/10.1063/1.1716296>
 852
- 853 Midtvedt, T., Lingaas, E., Carlstedt-Duke, B., Höverstad, T., Midtvedt, A. C.,
 854 Saxerholt, H., et al. (1990). Intestinal microbial conversion of cholesterol to
 855 coprostanol in man. Influence of antibiotics. *APMIS : Acta Pathologica,*
 856 *Microbiologica, Et Immunologica Scandinavica*, 98(9), 839–844.
 857
- 858 Miettinen, T. A., Ahrens, E. H., & Grundy, S. M. (1965). Quantitative isolation and
 859 gas-liquid chromatographic analysis of total dietary and fecal neutral steroids.
 860 *Journal of Lipid Research*, 6, 411–424.
 861
- 862 Monleon, D., Morales, J. M., Barrasa, A., Lopez, J. A., Vazquez, C., & Celda, B.
 863 (2009). Metabolite profiling of fecal water extracts from human colorectal
 864 cancer. *NMR in Biomedicine*, 22(3), 342–348.
 865
- 866 Mukherji, A., Kobiita, A., Ye, T., & Chambon, P. (2013). Homeostasis in intestinal
 867 epithelium is orchestrated by the circadian clock and microbiota cues
 868 transduced by TLRs. *Cell*, 153(4), 812–827.
 869 <http://doi.org/10.1016/j.cell.2013.04.020>
 870
- 871 Ndagijimana, M., Laghi, L., Vitali, B., Placucci, G., Brigidi, P., & Guerzoni, M. E.
 872 (2009). Effect of a synbiotic food consumption on human gut metabolic profiles

evaluated by ^1H Nuclear Magnetic Resonance spectroscopy. *International journal of food microbiology*, 134(1), 147-153.

O'Hara, A. M., & Shanahan, F. (2006). The gut flora as a forgotten organ. *EMBO Reports*, 7(7), 688-693. <http://doi.org/10.1038/sj.embor.7400731>

Owen, R. W., Thompson, M. H., & Hill, M. J. (1984). Analysis of metabolic profiles of steroids in faeces of healthy subjects undergoing chenodeoxycholic acid treatment by liquid-gel chromatography and gas-liquid chromatography-mass spectrometry. *Journal of Steroid Biochemistry*, 21(5), 593-600.

Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A., & Brown, P. O. (2007). Development of the human infant intestinal microbiota. *PLoS Biol*, 5(7), e177.

Perwaiz, S., Mignault, D., Tuchweber, B., & Yousef, I. M. (2002). Rapid and improved method for the determination of bile acids in human feces using MS. *Lipids*, 37(11), 1093-1100.

Phua, L. C., Chue, X. P., Koh, P. K., Cheah, P. Y., Ho, H. K., & Chan, E. C. Y. (2014). Non-invasive fecal metabonomic detection of colorectal cancer. *Cancer biology & therapy*, 15(4), 389-397.

Phua, L. C., Koh, P. K., Cheah, P. Y., Ho, H. K., & Chan, E. C. Y. (2013). Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based

metabonomic profiling of lyophilized human feces. *Journal of Chromatography B*, 937, 103-113.

Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal bacteria. *Journal of Lipid Research*, 47(2), 241–259. <http://doi.org/10.1194/jlr.R500013-JLR200>

Romick-Rosendale, L. E., Goodpaster, A. M., Hanwright, P. J., Patel, N. B., Wheeler, E. T., Chona, D. L., & Kennedy, M. A. (2009). NMR-based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad-spectrum antibiotic enrofloxacin (Baytril). *Magnetic Resonance in Chemistry : MRC*, 47 Suppl 1, S36–46. <http://doi.org/10.1002/mrc.2511>

Saric, J., Wang, Y., Li, J., Coen, M., Utzinger, J., Marchesi, J. R., et al. (2008). Species variation in the fecal metabolome gives insight into differential gastrointestinal function. *Journal of Proteome Research*, 7(1), 352–360. <http://doi.org/10.1021/pr070340k>

Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., et al. (2013). Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. *Cell Metabolism*, 17(2), 225–235. <http://doi.org/10.1016/j.cmet.2013.01.003>

Scherer, M., Böttcher, A., & Liebisch, G. (2011). Lipid profiling of lipoproteins by electrospray ionization tandem mass spectrometry. *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*, 1811(11), 918-924.

Schiller, J., & Arnold, K. (2002). Application of high resolution ³¹P NMR spectroscopy to the characterization of the phospholipid composition of tissues and body fluids-a methodological review. *Medical Science Monitor*, 8(11), MT205-MT222.

Schiller, J., Muller, M., Fuchs, B., Arnold, K., & Huster, D. (2007). ³¹P NMR spectroscopy of phospholipids: From micelles to membranes. *Current Analytical Chemistry*, 3(4), 283-301.

SScott, K. P., Duncan, S. H., & Flint, H. J. (2008). Dietary fibre and the gut microbiota. *Nutrition Bulletin*, 33(3), 201-211.

Setchell, K. D., Lawson, A. M., Tanida, N., & Sjövall, J. (1983). General methods for the analysis of metabolic profiles of bile acids and related compounds in feces. *Journal of Lipid Research*, 24(8), 1085-1100

Sigruener, A., Kleber, M. E., Heimerl, S., Liebisch, G., Schmitz, G., & Maerz, W. (2014). Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. *PloS one*, 9(1), e85724.

- Sonnenburg, E. D., & Sonnenburg, J. L. (2014). Starving our Microbial Self: The Deleterious Consequences of a Diet Deficient in Microbiota-Accessible Carbohydrates. *Cell Metabolism*, 20(5), 779–786. <http://doi.org/10.1016/j.cmet.2014.07.003>
- Snog-Kjaer, A., Prange, I., & Dam, H. (1956). Conversion of cholesterol into coprosterol by bacteria in vitro. *Journal of General Microbiology*, 14(2), 256–260.
- Spritz, N., Ahrens, E. H., & Grundy, S. (1965). Sterol balance in man as plasma cholesterol concentrations are altered by exchanges of dietary fats. *Journal of clinical investigation*, 44(9), 1482–1493.
- Story, J. A., & Furumoto, E. J. (1991). Bile acid analysis: methods and problems. *European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)*, 1 Suppl 2, 29–33.
- Su, X., Wang, N., Chen, D., Li, Y., Lu, Y., Huan, T., & Li, L. (2016). Dansylation isotope labeling liquid chromatography mass spectrometry for parallel profiling of human urinary and fecal submetabolomes. *Analytica chimica acta*, 903, 100–109.
- Tian, Y., Zhang, L., Wang, Y., & Tang, H. (2011). Age-related topographical metabolic signatures for the rat gastrointestinal contents. *Journal of proteome research*, 11(2), 1397–1411.

Trauner, M., Claudel, T., Fickert, P., Moustafa, T., & Wagner, M. (2010). Bile acids as regulators of hepatic lipid and glucose metabolism. *Digestive Diseases*, 28(1), 220-224.

Voigt, R. M., Forsyth, C. B., Green, S. J., Mutlu, E., Engen, P., Vitaterna, M. H., et al. (2014). Circadian disorganization alters intestinal microbiota. *PloS One*, 9(5), e97500. <http://doi.org/10.1371/journal.pone.0097500>

Weir, T. L., Manter, D. K., Sheflin, A. M., Barnett, B. A., Heuberger, A. L., & Ryan, E. P. (2013). Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. *PloS one*, 8(8), e70803.

Wenk, M. R. (2010). Lipidomics: New Tools and Applications. *Cell*, 143(6), 888–895. <http://doi.org/10.1016/j.cell.2010.11.033>

Wu, J., An, Y., Yao, J., Wang, Y., & Tang, H. (2010). An optimised sample preparation method for NMR-based faecal metabonomic analysis. *Analyst*, 135(5), 1023-1030.

Yap, I. K. S., Li, J. V., Saric, J., Martin, F.-P., Davies, H., Wang, Y., et al. (2008). Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. *Journal of Proteome Research*, 7(9), 3718–3728. <http://doi.org/10.1021/pr700864x>

- Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., et al. (2012). Human gut microbiome viewed across age and geography. *Nature*, 486(7402), 222–227. <http://doi.org/10.1038/nature11053>
- Zhao, Y. Y., Zhang, L., Long, F. Y., Cheng, X. L., Bai, X., Wei, F., & Lin, R. C. (2013). UPLC-Q-TOF/HSMS/MS E-based metabonomics for adenine-induced changes in metabolic profiles of rat faeces and intervention effects of ergosta-4, 6, 8 (14), 22-tetraen-3-one. *Chemico-biological interactions*, 201(1), 31-38.
- Zhao, Y., Wu, J., Li, J. V., Zhou, N. Y., Tang, H., & Wang, Y. (2013). Gut microbiota composition modifies fecal metabolic profiles in mice. *Journal of proteome research*, 12(6), 2987-2999.
- Zheng, X., Qiu, Y., Zhong, W., Baxter, S., Su, M., Li, Q., ... & Zeisel, S. H. (2013). A targeted metabolomic protocol for short-chain fatty acids and branched-chain amino acids. *Metabolomics*, 9(4), 818-827.

FIGURE CAPTIONS

Figure 1: Estimated proportion of fecal cholesterol derivatives in humans.

Figure 2: Neutral loss (NL) of 189 of lipid extracts prepared from fecal samples. Suspensions of human fecal samples in water/methanol (1/1) were subjected to bead-based homogenization. Homogenates were extracted according to Bligh and Dyer (Bligh & DYER, 1959). Crude lipid extracts were analyzed by direct flow injection analysis as described previously (Matyash et al., 2008). Displayed are NL 189 spectra, specific for phosphatidylglycerol (PG), of three different samples normalized to the highest intensity.

Table 1: Summary of published studies applying metabolomics to study fecal samples using NMR and MS platforms. Summary of protocols and main outcomes are included.


Key: GC-FID: Gas chromatography- Flame ionization detector; GC-MS: Gas chromatography-Mass spectrometry; LC-MS: Liquid chromatography-Mass spectrometry; UPLC-MS: Ultra-Performance Liquid Chromatography-Mass spectrometry

Analytical technique	Study aim	Sample preparation overview	Material / buffer	Measurement	Main results	References
NMR 400 MHz	Aging in mice	1:4 (wN/Av) feces in deuterated PBS + two filtration step	60 µL deuterated PBS containing 2 mM TSP in 600 µL of extract	TOCSY & HSQC	Aging induces ↑ 4-hydroxyphenylacetate, histidine, formate, succinate and ↓ α-ketoisocaproate, α-ketoisovalerate, -hydroxybutyrate, bile salts, isoleucine, methionine	Calvani et al., 2014
	Colorectal cancer human	1:3 (wN/Av) feces in deuterated PBS + vortexing and centrifugation	50 µL TSP (4 mM) in D2O added in 500 µL supernatant	N/A	N/A	Bezabeh et al. 2009
NMR 500 MHz	Experimental optimisation, mice	1:10 mg.µL ⁻¹ feces-to-buffer ratio, tissuelyser	N/A	COSY, TOCSY, HSQC, HMBC	Identification of 40 metabolites	Wu et al., 2010
NMR 600 MHz	Ulcerative colitis activity, humans	1:2 (WN/Av) feces to PBS, vortexing, centrifugation and filtration	4 µL of D2ON/A500 µM TSP with 40 µL of fecal extract	CPMG	Active UC induces ↑ BCAAs, lysine, alanine, taurine	Bjerrum et al. 2014
	Antibiotic treatment (gentamicine, ceftriaxone), mice	1:10 feces to PBS, freeze-thaw treatment, tissuelysr, centrifugation	30% D2O, 0.002% TSP, 0.03% of Na3N (wN/Av)	COSY, TOCSY, JRES, HSQC, HMBC	Antibiotic induces ↑ oligosacharides. phenolic acids and ↓ SCFAs, uracil, hypoxanthine	Zhao et al., 2013
	Age, rat	1:10 feces to PBS, vortexing, freeze-thaw, tissuelyser, centrifugation	0.1 M K2HPO4N/ANaH2PO4, pH = 7.4, containing 10% D2O, 0.58 mM TSP	COSY, TOCSY, HSQC, HMBC, DOSY	Aging induces ↓ arabinose, xylose, galactose, arabinoxylan, propionate and inosine and ↑ taurine, xylose, arabinose, galactose, arabinoxylans	Tian et al., 2012
	Infection <i>Schistosoma</i>	2 fecal pellets homogenized in	PBS containing 0.01% TSP	CPMG, COSY, TOCSY	Infection induces ↑ 5-Aminovalerate, SCFAs	Li et al., 2011

<i>mansoni</i> , mice	700 µL PBS, sonication, centrifugation				(propionate)	
IBS and UC, human	1:50 (wN/Av) feces to PBS, centrifugation, filtration	deuterated PBS containing 1 mM TSP	COSY, HSQC, HMBC	UC induces ↑ taurine and cadaverine, IBS induces ↑ bile acids and ↓ BCFAs		Le Gall et al., 2011
ProN/Aprebiotics, mice	1:12 (wN/Av) mashed feces to PBS, centrifugation	60 µL DSS (5 mM) in D2O added in 600 µL supernatant	TOCSY, HMBC, HSQC	Prebiotic induces ↓ threonine, alanine, glutamate, glutamine, aspartate, lysine, lycine, butyrate, uracil, hypoxanthine and ↑ monosaccharides, glucose, trimethylamine. Pre and probiotic ↓ trimethylamine and ↑ acetate, butyrate, glutamine	Cancer induces ↓ acetate, butyrate	Hong et al., 2010
Colorectal cancer, human	1:2 feces to distilled water, homogenization, freezing, thawing, centrifugation	100 µL D2O to 500 µL fecal water	TOCSY			Monleon et al., 2009
Grape juice and wine extract consumption, human	1:20 (wN/Av) feces to cold D2O or CD3OD, vortexing, centrifugation	D2O or CD3OD containing 1 mM TSP	CPMG		Grape juice consumption + wine induces ↓ isobutyrate	Jacobs et al., 2008
Effect of Species, storage, lyophilization, sonication, filtration and homogenisation	N/A	N/A	COSY, TOCSY, HSQC, HMBC		Storage: ↑ alanine, glutamate, threonine, aspartic acid, BCAAs, glucose. Lyophilization: ↑ BCAAs and ↓ succinate, SCFAs. Sonication: ↑ uracil, glucose and ↓ SCFAs	Saric et al., 2008
UC, human	1:2 (wN/Av) feces to PBS, vortexing, filtration, centrifugation	200 µL buffer (10% D2O & 0.01% TSP) in 400 µL fecal water	COSY, TOCSY		UC induces ↓ acetate, butyrate, methylamine, TMA and ↑ isoleucine, leucine, lysine	Marchesi et al., 2007

NMR 700 MHz	<i>Lactobacillus</i>	1:2 (wN/Av) feces to deuterated PBS, tissue lyser, centrifugation	Fecal water extracted in 9:1 D2O/AH2O and 0.05 % TSP	Noesy	<i>L. helveticus</i> induces ↑ butyrate, lactate and increased <i>Lactobacillus</i> level induces ↑ phenylalanine, tyrosine, lysine, lactate, propionate, valine, leucine, isoleucine, butyrate, acetate.	Le Roy et al., 2015
NMR 850 MHz	Baytrill treatment, mice	1:2 (wN/Av) feces to PBS, vortexing, centrifugation	200 µL buffer 10% D2O and 0.01% TSP in 400 µL fecal water	CPMG	Treatment induces ↓ alanine, butyrate, isoleucine, leucine, propionate, threonine, valine and ↑ urea	Romick-Rosendale et al., 2009
GC-MS	Colorectal cancer human	oximation and silylation	lyophilized human feces	N/A	Cancer patients ↓ butyrate, poly and monounsaturated fatty acids, ursodeoxycholic acid and ↑ acetate, amino acids	Weir et al., 2013
	VOCs irritable bowel syndrome, active Crohn's disease, ulcerative colitis	SPME	human feces	N/A	240 metabolites; esters of short chain fatty acids, cyclohexanecarboxylic acid associated with irritable bowel syndrome	Ahmed, Greenwood, de Lacy Costello, Ratcliffe, & Probert, 2013
	technical paper	trimethylsilylation	human fecal water	N/A	133 compounds structurally confirmed; 33 quantified	Gao, Pujos-Guillot, & Sébédio, 2010
	technical paper	ethyl chloroformate derivatization	human fecal water	N/A	73 compounds identified; 34 validated by reference standards	Gao et al., 2009
GC-TOF-MS	technical paper	oximation and silylation	lyophilized human feces	N/A	107 metabolites matched with mass spectra libraries, influence of blood on fecal metabolome	Phua, Koh, Cheah, Ho, & Chan, 2013
	Colorectal cancer human	oximation and silylation	lyophilized human feces	N/A	fecal metabolomic profiles of patients clearly differ from healthy subjects	Phua et al., 2014
GC-MS, GC-FID	VOCs, technical paper	SPME	human feces	N/A	evaluation of eight different commercially available SPME	Dixon et al., 2011

					fibers	
UPLC-MSN/ATOF-MS	liver cirrhosis, hepatocellular carcinoma	homogenization, centrifugation, filtration	human feces	N/A	Cancer patients ↓ chenodeoxycholic acid, 7-ketolithocholic acid, urobilinogen, urobilin and ↑ lysophosphatidylcholine (LPC) 16:0 and 18:0	Cao et al., 2011
UHPLC-TOF-MS	Effect of consumption of red wine	mixing with saline solution, centrifugation, filtration	human feces	N/A	37 metabolites related to wine intake	Jiménez-Girón et al., 2015
UPLC-Q-TOF-MS	chronic renal failure	homogenization, extraction with acetonitrile	rat feces	N/A	renal failure ↑ chenodeoxycholic acid, palmitic acid, adenine, phytosphingosine, monoglycerol 24:1, 12-hydroxy-3-oxocholadienic acid, lysophosphatidylethanolamine 18:2 and 16:0 and ↓ 7-ketolithocholic acid	Zhao, Cheng, Wei, Bai, & Lin, 2012
LC-MS, LC-UV	technical paper	Dried fecal samples extraction with water and acetonitrile, derivatization with dansyl chloride	human feces	N/A	67 metabolites (mainly amino acids) identified	Su et al., 2015



Minor fecal cholesterol derivatives

